Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Open Label, Expansion Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast and Liver Tumours.

Next Previous
Search
Trial Profile

A Phase Ib Open Label, Expansion Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast and Liver Tumours.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CUDC 101 (Primary)
  • Indications Breast cancer; Gastric cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker

    • Most Recent Events

    • 17 May 2012 Results will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology, according to a Curis media release.
    • 17 May 2012 New source identified and integrated (M.D. Anderson Cancer Center 2010-0483).
    • 17 May 2012 Planned number of patients changed from 40 to 50 as reported by M.D. Anderson Cancer Center record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top